Preparing early for acquisition: how biotech companies can build value long before a deal

Perparing early for acquisition playbook header.jpg

The strongest acquisition outcomes are shaped years before conversations with acquirers begin. Every development decision provides opportunity, yet many biotechs focus so intently on the next clinical milestone that they often miss the chance to build value along the way.

This playbook from Parexel and Health Advances shows you how to see your asset the way an acquirer will. Discover how to build deal-ready evidence, de-risk program vulnerabilities and create a value story that differentiates your innovation.
 

Download the playbook

Return to Insights Center